Sarah Olmstead

Sarah completed her PhD in Behavioral Neuroscience at the University of South Carolina under an interdisciplinary T32 grant. She was also a post-doctoral T32 awardee at the Johns Hopkins University, where she demonstrated that sleep fragmentation results in neuroinflammation independent of disease. After her postdoctoral work, she worked as a Principal Scientist at Longevity Biotech where she investigated the contribution of the adaptive immune system on neurodegenerative diseases and the efficacy of a novel peptide drug. Her career has focused on the effects of neuroinflammation on development and its contribution to neurological disease. Both her technical and analytical expertise, in addition to her grantsmanship, have contributed to more than $10 million in grant funding over the course of her career.